更新于：2024-06-24
Leramistat
更新于：2024-06-24
概要
基本信息
非在研机构- |
最高研发阶段临床2期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
结构
分子式C20H21ClN2O3S |
InChIKeyPHOYDFRXZMNHIF-IRJFHVNHSA-N |
CAS号1642602-54-7 |
关联
6
项与 Leramistat 相关的临床试验A Phase 1, Open-label, 3-Part, Drug-Drug Interaction Study to Evaluate the Effects of Inhibition and Induction of CYP3A4 on the Pharmacokinetics of Leramistat and to Assess the Effect of Leramistat on the Pharmacokinetics of Simvastatin in Healthy Adult Subjects
A DDI study consisting of 3 parts conducted as an open label, fixed sequence study in healthy adult subjects.
开始日期2024-04-08 |
申办/合作机构 |
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Investigate the Efficacy and Safety of Leramistat in Patients With Idiopathic Pulmonary Fibrosis (IPF)
To compare the effect of daily oral dosing of leramistat over 12 weeks with placebo in participants aged 40 years or older with idiopathic pulmonary fibrosis (IPF).
开始日期2023-08-30 |
申办/合作机构 |
An open label, single-dose, single-period study designed to assess the pharmacokinetics and mass balance recovery, metabolite profile and metabolite identification of ([Cyclohexane-U-14C]-MBS2320) in healthy male subjects
开始日期2022-09-08 |
申办/合作机构 |
100 项与 Leramistat 相关的临床结果
登录后查看更多信息
100 项与 Leramistat 相关的转化医学
登录后查看更多信息
100 项与 Leramistat 相关的专利（医药）
登录后查看更多信息
2
项与 Leramistat 相关的新闻（医药）2023-01-09
The dynamics of the rheumatoid arthritis market are anticipated to change in the coming years owing to the increasing awareness and expected increase in investment in the R&D activities. Companies like GlaxoSmithKline [Otilimab (MOR103/GSK3196165)], Taisho Pharmaceutical [Ozoralizumab (TS-152)], Aclaris Therapeutics [Zunsemetinib (ATI-450)], Abivax [ABX464], and others with their key candidates are in the late clinical and filing stage.
LAS VEGAS, Jan. 9, 2023 /PRNewswire/ -- DelveInsight's
Rheumatoid Arthritis Market Insights report includes a comprehensive understanding of current treatment practices, rheumatoid arthritis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into the 7MM [the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Key Takeaways from the Rheumatoid Arthritis Market Report
As per DelveInsight analysis, the rheumatoid arthritis market size in the 7MM was approximately
USD 27 billion in 2021.
According to the assessment done by DelveInsight, the estimated total rheumatoid arthritis prevalent population in the 7MM was approximately
4.
7 million in 2021.
Leading rheumatoid arthritis companies such as
Taisho Pharmaceuticals, R-Pharm, GlaxoSmithKline, Aclaris Therapeutics, Pfizer, Abivax, Bristol Myers Squibb, Oscotec/Genosco, Mesoblast, Pfizer Akros Pharma/Japan Tobacco, Abbvie, Horizon Therapeutics, Eli Lilly and Company, Taiho Pharmaceutical, Gilead Sciences, Kiniksa Pharmaceuticals, Istesso, SynAct Pharma, Cyxone, and others are developing novel rheumatoid arthritis drugs that can be available in the rheumatoid arthritis market in the coming years.
The promising rheumatoid arthritis therapies in the pipeline include
Ozoralizumab (TS-152),
Artlegia (Olokizumab),
Otilimab (GSK3196165/MOR103),
Zunsemetinib (ATI-450),
Ritlecitinib (PF-06651600),
ABX464,
Branebrutinib,
Cevidoplenib (SKI-O-703),
MPC-300-IV,
PF-06650833,
JTE -051,
ABBV-154,
TAS5315,
MBS2320,
AMT-101,
AP1189,
Rabeximod (Rob 803), and others.
In
June 2022, Cyxone received a response from a Type B Pre-IND meeting with the US FDA. The response from the FDA facilitates Cyxone to continue planning the Phase IIb study with Rabeximod in RA.
In
December 2021,
Taisho Pharmaceuticals presented the interim results from a 24-week administration in Phase II/III clinical trial (OHZORA study) of ozoralizumab in adult patients with RA at the annual meeting of the Japanese Society for Clinical Rheumatology and Related Research.
Discover which therapies are expected to grab the major rheumatoid arthritis market share @
Rheumatoid Arthritis Market Report
Rheumatoid Arthritis Overview
Rheumatoid arthritis is a type of autoimmune disease. It happens when our immune system, which is supposed to defend us, malfunctions and starts attacking our own tissues. It causes inflammation in the joint lining (the synovium). As a result, joints may become red, warm, swollen, and painful, which are all symptoms of rheumatoid arthritis. The precise causes of rheumatoid arthritis are still unknown.
Because the early signs and symptoms of rheumatoid arthritis are similar to those of many other diseases, it can be difficult to detect in its early stages. There is no single blood test or physical finding that can confirm the diagnosis of rheumatoid arthritis.
There is no known cure for rheumatoid arthritis. However, clinical trials of rheumatoid arthritis show that remission of symptoms is more common when rheumatoid arthritis treatment with disease-modifying antirheumatic medicines begins early (DMARDs).
Rheumatoid Arthritis Epidemiology Segmentation
DelveInsight estimates that there were approximately
4.7 million prevalent cases of rheumatoid arthritis in the 7MM in 2021.
Among the EU4 and the UK countries, Germany accounted for the highest number of rheumatoid arthritis cases, whereas France accounted for the lowest cases in 2021
The
rheumatoid arthritis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
Total Prevalent Cases
Total Diagnosed Prevalent Cases
Gender-specific Prevalent Cases
Age-specific Prevalent Cases
Severity-specific Prevalent Cases
Patients on Targeted Therapies
Line-Wise Treated Cases
Download the report to understand which factors are driving rheumatoid arthritis epidemiology trends @
Rheumatoid Arthritis Epidemiological Insights
Rheumatoid Arthritis Treatment Market
Over the last few years, there has been a dramatic improvement in rheumatoid arthritis outcomes as a direct result of paradigm shifts in rheumatoid arthritis treatment. At the moment, the main rheumatoid arthritis treatment options are
Medicine (for long-term relief of symptoms and slowing the progression of the condition),
Supportive treatments (including physiotherapy and occupational therapy, to help keep the patient mobile and manage any problems related to daily activities), and
Surgery (to correct any joint problems that develop over a period of time).
Nonsteroidal anti-inflammatory drugs (NSAIDs) are typically used only for symptomatic treatment until a rheumatoid arthritis diagnosis is established because they reduce pain and stiffness in patients but have no effect on disease progression.
Moreover, disease-modifying antirheumatic drugs (DMARDs) are used to target inflammation and prevent further joint damage and disease progression. DMARDs are a class of drugs that have been shown to affect the underlying cause of rheumatoid arthritis by reducing immune system overactivity, thereby alleviating pain, swelling, and stiffness and preventing joint changes. DMARDs can be prescribed singly or in combination as an initial part of treatment.
Methotrexate is the first-line DMARD agent for the majority of rheumatoid arthritis patients. It has a relatively quick onset of action at therapeutic doses (6-8 weeks), good efficacy, a low toxicity profile, is easy to administer, and is relatively inexpensive.
To know more about rheumatoid arthritis guidelines, visit @
Rheumatoid Arthritis Management
Rheumatoid Arthritis Pipeline Therapies and Key Companies
Artlegia (Olokizumab): R-Pharm
TS-152 (Ozoralizumab): Taisho Pharmaceuticals
Otilimab (GSK3196165/MOR103): GlaxoSmithKline
ATI-450 (Zunsemetinib/CDD-450): Aclaris Therapeutics
Branebrutinib: Bristol Myers Squibb
LY3462817: Eli Lilly and Company
TAS5315: Taiho Pharmaceutical
Rabeximod (Rob 803): Cyxone
GS-5718: Gilead Sciences
KPL-404: Kiniksa Pharmaceuticals
MBS2320: Istesso
AMT-101: Applied Molecular Transport
Dazodalibep (HZN-4920): Horizon Therapeutics
Cevidoplenib (SKI-O-703): Genosco/Oscotec
HB-AdMSCs: Hope Biosciences
ABX464: Abivax
MPC-300-IV: Mesoblast
PF-06650833: Pfizer
JTE 051: Akros Pharma/Japan Tobacco
Dekavil (F8IL10): Pfizer/Philogen
ABBV-154: AbbVie
PF-06651600 (Ritlecitinib): Pfizer
AP1189: SynAct Pharma
Learn more about the FDA-approved drugs for rheumatoid arthritis @
Drugs for Rheumatoid Arthritis Treatment
Rheumatoid Arthritis Market Dynamics
The dynamics of the rheumatoid arthritis market is anticipated to change in the future due to the
increasing awareness and
expected increase in investment in the R&D activities by the leading companies working in the rheumatoid arthritis market space. Moreover, current therapies, such as
biological DMARDs, have shown promising results in treating rheumatoid arthritis patients, and market penetration is expected to increase in the future, driving rheumatoid arthritis market growth.
Furthermore, there is still a high demand for therapies with a similar efficacy profile to current therapies but a better safety profile and a more patient-friendly RoA. Oral classes, such as
JAKi and the upcoming
BTKi, are expected to contribute to the rheumatoid arthritis market growth due to patient-friendly RoA.
However, several factors are likely to hamper the rheumatoid arthritis market growth. The rheumatoid arthritis market is
highly competitive, and new entrants are expected to face some resistance and low uptake because anti-TNFs currently dominate the rheumatoid arthritis market, and the
entry of biosimilars will pose significant challenges to new and upcoming treatment options in the rheumatoid arthritis market.
In addition, the entry of biosimilars has already begun in the US and EU (i.e.,
Remicade biosimilars), and as a result,
sales value has started to decline. The impact will be more pronounced when biosimilars/ generics of some blockbuster drugs, such as
Humira (i.e., 2023 in the US),
Xeljanz (i.e., 2025 in the US), will enter the rheumatoid arthritis market, and this will significantly impact the growth of the rheumatoid arthritis market.
Scope of the
Rheumatoid Arthritis
Market Report
Therapeutic Assessment: Rheumatoid Arthritis current marketed and emerging therapies
Rheumatoid Arthritis
Market Dynamics: Rheumatoid Arthritis market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL's views, Analyst's views, Rheumatoid Arthritis Market Access and Reimbursement
Discover more about rheumatoid arthritis drugs in development @
Rheumatoid Arthritis Clinical Trials
Table of Contents
Related Reports
Rheumatoid Arthritis Epidemiology Forecast
Rheumatoid Arthritis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted rheumatoid arthritis epidemiology in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Juvenile Rheumatoid Arthritis Pipeline
Juvenile Rheumatoid Arthritis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products and the key juvenile rheumatoid arthritis companies, including
Novartis, AbbVie, Eli Lilly and Company, Sanofi, among others.
Juvenile Rheumatoid Arthritis Market
Juvenile Rheumatoid Arthritis Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key juvenile rheumatoid arthritis companies, including
Novartis, AbbVie, Eli Lilly and Company, Sanofi, among others.
Psoriatic Arthritis Pipeline
Psoriatic Arthritis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key psoriatic arthritis companies, including
Mylan, Celltrion, Pfizer, Amgen, among others.
Psoriatic Arthritis Market
Psoriatic Arthritis Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key psoriatic arthritis companies, including
Mylan, Celltrion, Pfizer, Amgen, among others.
Other Trending Reports
Tay-sachs Disease Or Gm2 Gangliosidosis Market | Onycholysis Market | Diagnostic Imaging Equipment Market | Chemotherapy-induced Peripheral Neuropathy Market | Global Electrophysiology Devices Market | Anaphylaxis Market | Atherectomy Devices Market | Helicobacter Pylori Infections Market | Ophthalmic Imaging Equipment Market | Androgenetic Alopecia Market | Allergic Rhinitis Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Chronic Inflammtory Demyelinating Polyneuropathy Market | Colorectal Cancer Crc Market | Opioid Induced Constipation Market | Vertigo Market | Bone Anchored Hearing Systems Market | Wound Closure Devices Market | Hip Replacement Devices Market | Hemodynamic Monitoring Systems Market | Egfr Non-small Cell Lung Cancer Market | Helicobacter Pylori Infection Market | Hyperkalemia Market | Polycythemia Market Neurostimulation Devices Market | Carpal Tunnel Syndrome Market | Ventilator Market | Cerebral Aneurysm Market | Alpha Antitrypsin Market | Binge Eating Disorder Market | Bunion Market | Concussions Market Size | Exocrine Pancreatic Insufficiency Market | Healthcare Due Diligence Services | Minimal Residual Disease Market
Related Healthcare Blogs
Rheumatoid Arthritis Emerging Drugs
Knee Osteoarthritis Pipeline
Rheumatoid Arthritis Market Scenario
Juvenile Idiopathic Arthritis Therapy Market
Related Healthcare Services
Healthcare Business Consulting
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
.
Connect with us on LinkedIn
|Facebook|Twitter
Additionally, get in touch with our business executive to explore @
Healthcare Due Diligence Services
Contact Us
Shruti Thakur
[email protected]
+1(919)321-6187
Logo:
SOURCE DelveInsight Business Research, LLP
临床结果
2022-07-26
Rise in prevalence of rheumatoid arthritis, increase in demand for rheumatoid arthritis drugs, the entry of biosimilar drugs, the surge in geriatric population are the key factors driving the development of potential treatment of Rheumatoid arthritis. Major key players include Taisho Pharmaceutical, Zhejiang Hisun Pharmaceutical, SinoMab, Jiangsu Hengrui Medicine, RemeGen, GlaxoSmithKline, Modern Biosciences, Jiangsu Alphamab Biopharmaceuticals, and others.
LAS VEGAS, July 26, 2022 /PRNewswire/ -- DelveInsight's
'
Rheumatoid Arthritis Pipeline Insight 2022
' report provides comprehensive global coverage of available, marketed, and pipeline rheumatoid arthritis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the rheumatoid arthritis pipeline domain.
Key Takeaways from the Rheumatoid Arthritis Pipeline Report
DelveInsight's rheumatoid arthritis pipeline report depicts a robust space with
120+ active players working to develop
120 + pipeline therapies for rheumatoid arthritis treatment.
Key rheumatoid arthritis companies such as
Taisho Pharmaceutical, Zhejiang Hisun Pharmaceutical, SinoMab, Jiangsu Hengrui Medicine, RemeGen, GlaxoSmithKline, Modern Biosciences, Jiangsu Alphamab Biopharmaceuticals, Akros Pharma, Hanlim Pharm, Galapagos NV, Chong Kun Dang Pharmaceutical, Bristol Myers Squibb, AstraZeneca, Aclaris Therapeutics, Abivax, AbbVie, Synact Pharma, Gilead sciences, Mesoblast, Rottapharm Biotech, Eli Lilly and Company, Kiniksa Pharmaceuticals, Abcentra, Cyxone, Yungjin Pharm. Co., Ltd. Taiho Pharmaceutical, Oscotec Inc., Pfizer, Janssen Research & Development, Cipher Pharmaceuticals Inc., KLUS Pharma Inc., Revolo Biotherapeutics, Lynk Pharmaceuticals, Beijing Baylx Biotech, Hope Biosciences, Kangstem Biotech, Celltex Therapeutics, I-Mab Biopharma Co. Ltd., Synermore Biologics Co., Ltd, Oryn Therapeutics, Arthrogen, Bayer, Amgen, Draconis Pharma, Biozeus, Landos Biopharma, Imcyse, Kymera Therapeutics, RedHill Biopharma, 4D Pharma, CV6 Therapeutics, VYNE Therapeutics, MyMD Pharmaceuticals, Brickell Biotech Inc, Worg Pharmaceuticals, Almirall, Standigm, Metrion Biosciences, Jnana Therapeutics, Silo Pharma, SFA Therapeutics, Neutrolis Therapeutics, Ahead Therapeutics, Fresenius Kabi, Kidswell Bio, BioXpress Therapeutics, CinnaGen, Alvotech, Hetero Biopharma, Shanghai Henlius Biotech, Cadila Pharmaceuticals, Innovent Biologics, Torrent Pharmaceuticals, Emcure Pharmaceuticals, mAbxience, Shanghai Junshi Biosciences, Enosi Therapeutics, and others are evaluating novel rheumatoid arthritis treatment drugs candidate to improve the treatment landscape.
Promising rheumatoid arthritis pipeline therapies in various stages of development includes
TS152, HS-016, SM03, SHR0302, RC18, Otilimab, NI-0101, MBS2320, KN019, JTE-051, Interleukin 2, HL237, GLPG3970, Elsubrutinib, CKD-506, Branebrutinib, AZD9567, ATI-450, ABX464, ABBV 3373, ABBV 154, AP1189, F8IL10, AMT-101, GS-9876, CR 6086, LY 3462817, KPL-404, Orticumab, Rabeximod, YRA 1909, VIB4920, Varicella Zoster Vaccine, TAS5315, SKI-O-703, SAN-300, PF-06650833, Nipocalimab, CF-101, A223, IRL 201805, LNK 01001, PRTX-100, hUC-MSC infusion, HB-adMSC, LABP-104, VAY736, TJ003234 , SYN060, GS-5718, PF-06835375, Nivolumab, MH004, ORTD-1, ART-I02, FB704A, Amilo 5MER, CKD-374 , CFZ-533, BAY 1830839, AMG 570, JNJ-4703, CT-P47, BZ068, Invossa, LABP-69, ICM-203-R, NX-5948, KT-474 , Clarithromycin/clofazimine/rifabutin (RHB-104), Research programme: small molecule TYK2 inhibitors, MRx0006, CV6 1271, VYN201, MYMD-1, BBI 02, Research Programme: Immune mediated diseases, Foralumab, SPU-21, SFA002, NTR-441, Research programme: autoimmune disease therapeutics, AT_1001, MSB11456, MabionCD20, DMB-3113, GB232, GBS 005, TX17, BX 2922, Cinnora, AVT02, MYL-1401A, and others.
In July 2022,
Enosi Therapeutics, announced a partnership with
Danuo Science Group, based in Hong Kong, to further develop two products currently in Enosi's pipeline for Greater China.
Enosi's Growth Factor Trap (EN-2000 Program) and TNFR1 Blocker (EN-1000 Program) were licensed as part of the partnership. Both programs have the potential to be used as cross-over drugs to treat cancer and autoimmune diseases.
EN-2000 blocks inflammatory growth factors that drive cancer and
rheumatoid arthritis while EN-1000 is a specific blocker of TNFR1, which Enosi believes may be useful in treating autoimmune disease.
In February 2022,
Biogen Inc. and
Xbrane Biopharma AB announced that they have entered into a
commercialization and license agreement to develop, manufacture, and commercialize
Xcimzane™, a preclinical monoclonal antibody that is a proposed biosimilar referencing CIMZIA® (certolizumab pegol).
In
June 2022,
Biogen Inc. and Bio-Thera Solutions, Ltd. presented positive
Phase III data for
BIIB800 (BAT1806), a biosimilar candidate referencing. The double-blind 52-week Phase III study randomized 621 patients with moderate to severe rheumatoid arthritis to receive either BIIB800 or the reference tocilizumab administered intravenously every 4 weeks at a dose of 8 mg/kg for the first 24 weeks. Data from the Phase III comparative clinical trial demonstrated that the investigational biosimilar candidate BIIB800 has
equivalent efficacy and comparable safety and immunogenicity profile to the reference tocilizumab product.
In
June 2022,
Revolo Biotherapeutics announced that it was awarded an
Innovative Medicines Designation, or Innovation Passport, from the Medicines and Healthcare products Regulatory Agency (MHRA) for its immune-resetting drug candidate, '1805, for the treatment of patients with moderately to severely active Rheumatoid Arthritis (RA). In
February 2022,
Revolo Biotherapeutics secured
approval from the
UK Medicines and Healthcare products Regulatory Agency (MHRA) to initiate two
Phase II trials of its autoimmune disease
drug candidate '1805. One of the trials will enrol moderate-to-severe active rheumatoid arthritis (RA) patients while another Phase II trial will have individuals with non-infectious, active, intermediate, or posterior uveitis or panuveitis.
In
December 2021,
Theramex, entered into an agreement with
Enzene Biosciences Limited to develop, register, and commercialize a biosimilar drug of Roche's reference medicine RoActemra (Tocilizumab). Tocilizumab, in combination with Methotrexate (MTX), is indicated for the treatment of rheumatoid arthritis. It is planned to be commercialized from 2026 in Europe, the UK, Switzerland, and Australia.
Obefazimod is an oral, first-in-class, small molecule being
developed by
Abivax in
Phase II stage of development. Obefazimod generated
promising pre-clinical data from collagen-induced arthritis animal models that were the basis for moving into the Phase IIa clinical trial in rheumatoid arthritis (RA).
Zunsemetinib, an Investigational Oral MK2 Inhibitor, is being developed by Aclaris Therapeutics.
Aclaris initiated study activities and began activating sites in
December 2021 in the following two studies:
ATI-450-RA-202: Phase IIb clinical trial of zunsemetinib in subjects with moderate to severe rheumatoid arthritis (RA). This is Aclaris' second Phase II clinical trial of zunsemetinib in subjects with moderate to severe RA and is primarily
designed to assess the efficacy of multiple doses of zunsemetinib to aid in the selection of an optimal dose to progress in future development.
Request a sample and discover the recent advances in rheumatoid arthritis treatment @
Rheumatoid Arthritis Pipeline Outlook
The rheumatoid arthritis pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage rheumatoid arthritis products, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the rheumatoid arthritis pipeline landscape.
Rheumatoid Arthritis Overview
Rheumatoid arthritis is classified as an autoimmune disorder. It occurs when the immune system, which is supposed to defend, malfunctions and begins to attack our own tissues. It causes inflammation in the lining of the joints (the synovium). As a result, joints may become red, warm, swollen, and painful, which are common rheumatoid arthritis symptoms. The exact rheumatoid arthritis causes are still unknown.
Rheumatoid arthritis can be difficult to detect in its early stages since the early signs and symptoms are similar to those of many other diseases. There is no single blood test or physical finding that can validate the rheumatoid arthritis diagnosis.
Rheumatoid arthritis has no known cure. However, rheumatoid arthritis clinical trials show that remission of symptoms is more frequent when rheumatoid arthritis treatment with disease-modifying antirheumatic medicines started early (DMARDs).
Find out more about rheumatoid arthritis treatment @
Rheumatoid Arthritis Treatment Drugs
A snapshot of the Rheumatoid Arthritis Pipeline Drugs mentioned in the report:
Learn more about the novel and emerging rheumatoid arthritis pipeline therapies @
Rheumatoid Arthritis Clinical Trials
Rheumatoid Arthritis Therapeutics Assessment
The
rheumatoid arthritis pipeline report proffers an integral view of rheumatoid arthritis emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the Rheumatoid Arthritis Pipeline Report
Coverage: Global
Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Therapeutics Assessment
By Route of Administration: Intra-ocular, Intra-articular, Intrathecal, Intravenous, Oral, Parenteral, Ophthalmic, Subcutaneous, Topical, Transdermal
Therapeutics Assessment
By Molecule Type: Oligonucleotide, Peptide, Small molecule
Therapeutics Assessment
By Mechanism of Action: Interleukin 6 inhibitor, Tumour necrosis factor-alpha inhibitor, CD22 antigen inhibitor, Janus kinase 1 inhibitor, B cell activating factor inhibitor, Granulocyte-macrophage colony-stimulating factor antagonist, Toll-like receptor 4 antagonist, Emt protein-tyrosine kinase inhibitor, Fibroblast growth factor modulators; T lymphocyte inhibitors, Bacteria replacements.
Key Rheumatoid Arthritis Companies: Taisho Pharmaceutical, Zhejiang Hisun Pharmaceutical, SinoMab, Jiangsu Hengrui Medicine, RemeGen, GlaxoSmithKline, Modern Biosciences, Jiangsu Alphamab Biopharmaceuticals, Akros Pharma, Hanlim Pharm, Galapagos NV, Chong Kun Dang Pharmaceutical, Bristol Myers Squibb, AstraZeneca, Aclaris Therapeutics, Abivax, AbbVie, Synact Pharma, Gilead sciences, Mesoblast, Rottapharm Biotech, Eli Lilly and Company, Kiniksa Pharmaceuticals, Abcentra, Cyxone, Yungjin Pharm. Co., Ltd. Taiho Pharmaceutical, Oscotec Inc., Pfizer, Janssen Research & Development, Cipher Pharmaceuticals Inc., KLUS Pharma Inc., Revolo Biotherapeutics, Lynk Pharmaceuticals, Beijing Baylx Biotech, Hope Biosciences, Kangstem Biotech, Celltex Therapeutics, I-Mab Biopharma Co. Ltd., Synermore Biologics Co., Ltd, Oryn Therapeutics, Arthrogen, Amgen, Biozeus, Landos Biopharma, Imcyse, Kymera Therapeutics, RedHill Biopharma, 4D Pharma, CV6 Therapeutics, VYNE Therapeutics, MyMD Pharmaceuticals, Brickell Biotech Inc, Worg Pharmaceuticals, Almirall, Standigm, Metrion Biosciences, Jnana Therapeutics, Silo Pharma, SFA Therapeutics, Neutrolis Therapeutics, Ahead Therapeutics, Fresenius Kabi, Kidswell Bio, BioXpress Therapeutics, CinnaGen, Alvotech, Hetero Biopharma, Shanghai Henlius Biotech, Cadila Pharmaceuticals, Innovent Biologics, Torrent Pharmaceuticals, Emcure Pharmaceuticals, mAbxience, Shanghai Junshi Biosciences, Enosi Therapeutics, and others
Key Rheumatoid Arthritis Pipeline Therapies: TS152, HS-016, SM03, SHR0302, RC18, Otilimab, NI-0101, MBS2320, KN019, JTE-051, Interleukin 2, HL237, GLPG3970, Elsubrutinib, CKD-506, Branebrutinib, AZD9567, ATI-450, ABX464, ABBV 3373, ABBV 154, AP1189, F8IL10, AMT-101, GS-9876, CR 6086, LY 3462817, KPL-404, Orticumab, Rabeximod, YRA 1909, VIB4920, Varicella Zoster Vaccine, TAS5315, SKI-O-703, SAN-300, PF-06650833, Nipocalimab, CF-101, A223, IRL 201805, LNK 01001, PRTX-100, hUC-MSC infusion, HB-adMSC, LABP-104, VAY736, TJ003234 , SYN060, GS-5718, PF-06835375, Nivolumab, MH004, ORTD-1, ART-I02, FB704A, Amilo 5MER, CKD-374 , CFZ-533, BAY 1830839, AMG 570, JNJ-4703, CT-P47, BZ068, Invossa, LABP-69, ICM-203-R, NX-5948, KT-474 , Clarithromycin/clofazimine/rifabutin (RHB-104), Research programme: small molecule TYK2 inhibitors, MRx0006, CV6 1271, VYN201, MYMD-1, BBI 02, Research Programme: Immune mediated diseases, Foralumab, SPU-21, SFA002, NTR-441, Research programme: autoimmune disease therapeutics, AT_1001, MSB11456, MabionCD20, DMB-3113, GB232, GBS 005, TX17, BX 2922, Cinnora, AVT02, MYL-1401A, and others.
Dive deep into rich insights for drugs for rheumatoid arthritis, visit @
Rheumatoid Arthritis Medications
Table of Contents
For further information on the rheumatoid arthritis pipeline therapeutics, reach out @
Drugs for Rheumatoid Arthritis
Related Reports
Rheumatoid Arthritis Market
Rheumatoid Arthritis Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key rheumatoid arthritis companies including
Abivax, UCB, Sierra Oncology, Taisho, among others.
Rheumatoid Arthritis Epidemiology Forecast
Rheumatoid Arthritis Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical and forecasted rheumatoid arthritis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Juvenile Rheumatoid Arthritis Pipeline
Juvenile Rheumatoid Arthritis Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products and the key juvenile rheumatoid arthritis companies, including
Novartis, AbbVie, Eli Lilly and Company, Sanofi, among others.
Juvenile Rheumatoid Arthritis Market
Juvenile Rheumatoid Arthritis Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key juvenile rheumatoid arthritis companies including
Novartis, AbbVie, Eli Lilly and Company, Sanofi, among others.
Psoriatic Arthritis Pipeline
Psoriatic Arthritis Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key psoriatic arthritis companies, including
Mylan, Celltrion, Pfizer, Amgen, among others.
Psoriatic Arthritis Market
Psoriatic Arthritis Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key psoriatic arthritis companies including
Mylan, Celltrion, Pfizer, Amgen, among others.
Other Trending Reports
Persistent Depressive Disorder Market | Gene Therapy for Ocular Rare Disease Market | Congestive Heart Failure Market | CRISPR Therapies Pipeline | Desmoplastic Small Round Cell Tumors Market | India Healthcare Outlook Report | Psychosis Market | Dental Lasers Market | Primary Immune Deficiency Market I Dyslipidemia Market | Lateral Epicondylitis Disease Market | Castration-Resistant Prostate Cancer Market | Metrorrhagia Market | Global Messenger RNA-based Vaccines and Therapeutics Market | Negative Pressure Wound Therapy Systems Market | US Healthcare Outlook Report | Mucinous Cystic Neoplasms Market | Hot Flashes Market |
Varicose Veins - Market |
Hemostats Market | Injectable Drug Delivery Devices Market | Breast Pumps Market | Physiotherapy Equipment Market | Trastuzumab Biosimilars Insight | Deep Brain Stimulation Devices Market | Retinoblastoma Market | Venous Stenosis Market | Tumor Ablation Market | Substance Abuse Market | Insulin Glargine Biosimilar Insight | Interspinous Spacers Market | Anti-hypertension Market
Latest Healthcare Blogs
Knee Osteoarthritis Pipeline
Rheumatoid Arthritis Market Scenario
Juveline Idiopathic Arthritis Therapy Market
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences.
Connect with us at LinkedIn
Contact Us
Shruti Thakur
[email protected]
+1(919)321-6187
Logo:
SOURCE DelveInsight Business Research, LLP
100 项与 Leramistat 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 特发性肺纤维化 | 临床2期 | 美国 | 2023-08-30 | |
| 特发性肺纤维化 | 临床2期 | 法国 | 2023-08-30 | |
| 特发性肺纤维化 | 临床2期 | 德国 | 2023-08-30 | |
| 特发性肺纤维化 | 临床2期 | 希腊 | 2023-08-30 | |
| 特发性肺纤维化 | 临床2期 | 匈牙利 | 2023-08-30 | |
| 特发性肺纤维化 | 临床2期 | 以色列 | 2023-08-30 | |
| 特发性肺纤维化 | 临床2期 | 意大利 | 2023-08-30 | |
| 特发性肺纤维化 | 临床2期 | 西班牙 | 2023-08-30 | |
| 特发性肺纤维化 | 临床2期 | 英国 | 2023-08-30 | |
| 类风湿关节炎 | 临床2期 | 格鲁吉亚 | 2017-05-30 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床2期 | 96 | 艱襯積衊繭獵壓簾艱鏇(鹽餘願獵襯艱襯鏇醖淵) = 觸觸選糧醖鏇鏇選艱窪 簾憲網願衊選構選製遞 (艱遞襯網觸製鏇醖膚蓋 ) 更多 | 积极 | 2020-06-01 | |||
Placebo | 艱襯積衊繭獵壓簾艱鏇(鹽餘願獵襯艱襯鏇醖淵) = 願膚齋構積繭願鹽鏇糧 簾憲網願衊選構選製遞 (艱遞襯網觸製鏇醖膚蓋 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
标准版
¥16800
元/账号/年
新药情报库 ｜ 省钱又好用！
立即使用
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用